Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00165399 · ClinicalTrials.gov registry record · Phase 2
Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT00165399: Completed Phase 2 study, sponsored by Dana-Farber Cancer Institute.
NCT00165399 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 62 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00165399, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
The purpose of this study is to see if the combination of chemotherapy drugs and drugs to suppress testosterone (hormone therapy) is effective in controlling early prostate cancer. This study will attempt to: * stop or slow the growth of disease * gain information about prostate cancer * evaluate the effectiveness and side effects of the study drug
Interventions
- DRUG Docetaxel
- DRUG Zoladex
- DRUG Estramustine
- DRUG Casodex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2004-03 |
| Est. Completion | 2005-12-31 |
| Phase | Phase 2 |
What the finished NCT00165399 record still lists
NCT00165399 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 4 interventions - of which Docetaxel is the first listed.
NCT00165399 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00165399 about?
NCT00165399 is a clinical study titled "Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment". The purpose of this study is to see if the combination of chemotherapy drugs and drugs to suppress testosterone (hormone therapy) is effective in controlling early prostate cancer. This study will attempt to: * stop or slow the growth of disease * gain information about prostate cancer * evaluate ...
What is the current status of trial NCT00165399?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2004-03. Estimated completion is 2005-12-31.
What interventions are being tested in trial NCT00165399?
The interventions under investigation include: Docetaxel (DRUG), Zoladex (DRUG), Estramustine (DRUG), Casodex (DRUG).
Who is sponsoring clinical trial NCT00165399?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00165399's enrollment target sits among peer trials
62 1016th of 2000 higher than 975 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia